BioSpace

Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes amid reports of tension over a commissioner’s voucher for Sanofi’s diabetes drug. #FDA #vouchers #biospace hubs.li/Q04gR6n50

@Novartis is letting go of “a select number” of employees within its biomedical research organization, while Takeda is cutting 4,500 employees in fiscal year 2026. Learn more in our layoff tracker. #layoffs #biopharma #biospace hubs.li/Q04gN-3d0 hubs.li/Q04gN-3d0

California life sciences jobs dipped 1.8% last year, according to the new @CALifeSciences sector report. While National Institutes of Health funding and venture capital investment rose, growth slowed from the previous year. #jobmarket #biopharma #biospace hubs.li/Q04gN_cg0

Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish drugmaker ending development of another clinical program stemming from the buyout. #drugdevelopment #pharma #biospace hubs.li/Q04gNFS40

A batch of a chemotherapy product made at a Sun facility with a history of quality and compliance issues is being withdrawn from the U.S. market. #manufacturing #pharma #biospace hubs.li/Q04gNGbT0

If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter syndrome—could ensure the medicine gets where it needs to be for the greatest therapeutic impact, analysts said. #drugdevelopment #biospace hubs.li/Q04gNzpY0

Aardvark Therapeutics had previously voluntarily suspended studies of ARD-101—and a related asset called ARD-201—after detecting anomalous echocardiographic readings in healthy volunteers that could indicate reduced heart efficiency. hubs.li/Q04gM_790

CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical testing. #seriesb #preclinical #biospace hubs.li/Q04gM_p50

Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening platforms. #radiopharma #GPCR #biospace hubs.li/Q04gFSj40

Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday. #genetherapy #biospace hubs.li/Q04gD7RG0

Specialty vaccine maker @valnevaSE will trim its global workforce by 10% to 15% as it focuses resources on its base business and key strategic projects. Learn more in our layoff tracker. #layoffs #biopharma #biospace hubs.li/Q04gBCYR0

Average job postings live on BioSpace increased year over year for nearly every month of 2026, but the number of employees affected by made or planned layoffs by the end of that same period nearly matched 2025 numbers. #jobmarket #biopharma #biospace hubs.li/Q04gB-970

Looking for a biopharma job in California? Check out our list of 17 companies hiring life sciences professionals like you. #nowhiring #biopharma #biospace hubs.li/Q04gBHtl0

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts eager for more data. #alzheimers #biospace hubs.li/Q04gBdg00

In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to lead the agency after the departure of Marty Makary. #FDA #biotech #biospace hubs.li/Q04gy-MP0

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for undisclosed immune-mediated conditions. #seriesa #immunology #biospace hubs.li/Q04gyMKX0

Beqalzi is the first BCL2 inhibitor approved for relapsed or refractory mantle cell lymphoma. #drugapprovals #biospace hubs.li/Q04gyZ700

Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and Jon Ellis, co-founder & CEO of Trenchant Bios, speak live from the ISCT annual meeting. We dive into mesenchymal stem cells and induced pluripotent stem cells. hubs.ly/Q04gzkvC0

While Takeda is eliminating 4,500 roles across its global operations, the company has some 2,200 jobs currently open for hiring, for which internal candidates will be prioritized. #layoffs #pharma #biospace hubs.li/Q04gzx3-0

MacroGenics is selling the manufacturing plant to Bora, a Taiwan-based CDMO, to raise cash to support the progress of its drug development pipeline. #manufacturing #drugdevelopment #biospace hubs.li/Q04gvZB-0